Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Provectus Pharmaceuticals has received a patent in India protecting its lead oncology agent, PV-10, along with a number of related agents. The patent covers injectable and other forms of the drugs, including capsules, tablets, oral suspensions and solutions.
Subscribe to our email newsletter
A range of active compounds are protected, each related to the active ingredient in PV-10.
Provectus is currently conducting Phase II clinical trials of its proprietary drugs PV-10 as a therapy for melanoma and breast cancer.
Craig Dees, CEO of Provectus, said: “Obtaining patent protection in India for PV-10 and our additional pipeline products is a major milestone, assuring a viable route to access a market representing roughly one-fifth of the world’s population. Additionally, as the Indian pharmaceutical industry becomes a larger player in the worldwide market, this protection establishes an important right of ownership for products sold or made in India.”